Longeveron Inc. (LGVN)
1.52
-0.01 (-0.65%)
At close: Feb 28, 2025, 3:59 PM
1.87
22.97%
After-hours: Feb 28, 2025, 05:57 PM EST
No 1D chart data available
| Bid | 1.85 |
| Market Cap | 22.55M |
| Revenue (ttm) | 2.02M |
| Net Income (ttm) | -19.51M |
| EPS (ttm) | -5.62 |
| PE Ratio (ttm) | -0.27 |
| Forward PE | -1.05 |
| Analyst | Buy |
| Ask | 1.87 |
| Volume | 262,466 |
| Avg. Volume (20D) | 248,500 |
| Open | 1.53 |
| Previous Close | 1.53 |
| Day's Range | 1.45 - 1.56 |
| 52-Week Range | 0.77 - 6.40 |
| Beta | 0.35 |
About LGVN
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, a...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 12, 2021
Employees 23
Stock Exchange NASDAQ
Ticker Symbol LGVN
Website https://www.longeveron.com
Analyst Forecast
According to 3 analyst ratings, the average rating for LGVN stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 557.89% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Earnings Surprise
Longeveron has released their quartely earnings
on Feb 28, 2025:
Next Earnings Release
Longeveron Inc. is scheduled to release its earnings on Feb 28, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 day ago
Longeveron shares are trading higher after the com...
Unlock content with
Pro Subscription
7 months ago
+0.87%
Longeveron shares are trading higher after the company announced study results from the CLEAR MIND Phase 2a clinical trial of Lomecel-B in mild Alzheimer's disease, meeting its key objectives to advance data supporting a favorable benefit/risk profile.
